World s Largest Healthcare Services Platform

Transcription

1 Healthcare Overview

2 World s Largest Healthcare Services Platform July 1, 2013 Nypro became part of Jabil Our Mission is to be the World s Most Capable and Trusted Healthcare Services Company Jabil Healthcare & Instrumentation joined forces with Nypro Healthcare Combined team goes to market as Nypro Healthcare, A Jabil Company Headquartered in Clinton, Mass, Jabil will build upon Nypro s 40-year healthcare history Team of 8,000 colleagues in 23 locations in 11 countries 2

3 Nypro Healthcare 2016 NYPRO Healthcare A Recognizably Differentiated Healthcare Services Company We will become recognized as the World s most trusted and capable Healthcare Services company as evidenced by our strong partnerships and growth with the Leading Global Healthcare Companies. Our Global Platform will be the most efficient and capable in the Industry Jabil Healthcare & Instrumentation We have a passion for assisting our customers in unlocking their full potential by entrusting us to perform key services across their value chain. We start each day with the mission of providing Products and Services that sustain, improve, or extend the lives of people across the globe.

4 Jabil & Nypro - History

5 Delivering Global Services 23 Locations in 11 Countries = Manufacturing = Design * Both Manufacturing & Design USA Asheville, NC Auburn Hills, MI Chicago, IL Clinton, MA* Devens, MA (2014) Dallas, TX Mebane, NC St Petersburg, FL LATIN AMERICA Baja, Mexico Cayey, Puerto Rico Guadalajara, Mexico * Both Manufacturing & Design EUROPE Chartres,France Knittlingen,Germany Bray, Ireland* Waterford, Ireland (2014) Vienna, Austria* Hungary ASIA Shenzhen, China Shanghai, China* Penang, Malaysia Singapore City 5

6 Leader in Attractive, Growing Markets Capital Equipment Analytical Instrumentation Drug Delivery & Diagnostics Medical Devices & Consumer Health Anesthesia/Respiratory Surgical Fluid Delivery In Vitro Diagnostics Patient Monitoring Diagnostic Imaging Gas Chromatography Liquid Chromatography Mass Spectrometry Leak Detection systems Auto Injectors Dry Powder Inhalers Insulin Pens Metered Dose Inhalers Needle Free Injection Systems Diabetes Products Consumer Health Devices Surgical Devices Wound Care Devices Enteral Feeding Sets Angiography Sets 6

7 Significant Addressable Market Expansion with Nypro 50.0% 45.0% Healthcare Outsourcing Market Jabil Field of Play Nypro Field of Play 40.0% 35.0% 30.0% $ % 20.0% 15.0% $70.12 $88.41 Finished Device Outsourcing Electronics Outsourcing Plastic Injection Molding Plastic Extrusions 10.0% Metal Fabrication & Molding Outsourcing 5.0% Other material and mechanical Outsourcing 0.0%

8 Nypro Healthcare Drug Delivery & Diagnostics James O Gorman Vice President Drug Delivery & Diagnostics 8

9 Drug Delivery & Diagnostics Market Drug Delivery & Diagnostics Drug Delivery Market Diagnostics Market Inhalation Injectables Consumables Point of Care Patient Self Testing Gene Research 9

10 Top Market Leaders 10

11 Business Model Device Development Support Product Development Mold Fabrication Injection Molding Automated Assembly Full Production Drug / Reagent Handling Rigorous Quality Systems - for risk mitigation and regulatory compliance Design, system Integration, Industrialization & Program Management for effective launch & lifecycle management. Operational Excellence - to deliver global consistency and reliability Nypro Healthcare Confidential 11

12 Millions Units Development & Lifecycle of Drug Delivery Programs k compounds Drug Discovery Preclinical 250 compounds Phase I Clinical Trials Phase II Phase III 5 compounds FDA Approval Typical Business Engagement Timeline Pharma Award Biz NPI Prep Mass Production Large Scale Production Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 Y16 Y17 Y18 Y19 Y20 Y21 Y22 Y23 1 Drug Long Award-to-Production Timeline: typically 4~6 years Early Development and Launch Capabilities are Key to participation Due to Regulatory and development complexity, most awards Sole Source Upon Regulatory Approval Products have significant production life-cycles with little or no process changes. Site manufacture relocation (switching) is rare Returns - Margins reflect risk, revenue stream of a 8 ~10 years after lengthy start up incubation.

13 Nypro Healthcare - Drug Delivery and Diagnostics Summary We have differentiated, unique capabilities which are vital in the development and delivery of drugs treating Diabetes, COPD, and other major diseases. We have a Diversified Customer Base partnering with 80% of the World s Top ten Pharmaceutical companies and leading Generic companies. We have Unparalleled Capabilities on a Global Scale. We are well positioned for growth as smart devices and electronics converge into future Drug Delivery Devices.